NVO NOVO NORDISK A S

NYSE novonordisk.com


$ 54.58 $ -1.72 (-3.07 %)    

Friday, 17-Oct-2025 19:52:11 EDT
QQQ $ 604.92 $ 3.94 (0.66 %)
DIA $ 461.73 $ 2.22 (0.48 %)
SPY $ 665.28 $ 3.75 (0.57 %)
TLT $ 91.09 $ -0.14 (-0.15 %)
GLD $ 391.28 $ -7.46 (-1.88 %)
$ 54.37
$ 53.81
$ 54.58 x 118
$ 54.80 x 1,000
$ 53.54 - $ 54.44
$ 44.55 - $ 115.02
14,761,514
na
245.21B
$ 0.79
$ 17.49
TBD
na
na ($ 0.03)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-risk-reduction-in-adults-with-type-2-diabetes-who-are-at-high-risk-including-those-who-have-not-had-a-prior-cv-event

https://www.prnewswire.com/news-releases/fda-approves-novo-nordisks-oral-semaglutide-for-cardiovascular-cv-risk-reduction-in-ad...

 trumps-weight-loss-drug-push-may-put-these-etfs-on-a-diet

Trump's vow to slash weight-loss drug prices sent Hims & Hers tumbling. These ETFs are facing new pressure.

 trump-induced-volatility-aside-novo-trades-cheap-while-patents-protect-its-profits-until-2032

Novo Nordisk offers cheap stock with strong moat and long-term growth tailwinds. Trump's drug price cut suggestion caused s...

 novo-nordisk-stock-is-falling-friday-whats-driving-the-action

Shares of Danish pharmaceutical giant Novo Nordisk are trading lower Friday morning, continuing an after-hours slide that began...

 eli-lilly-shares-are-trading-lower-friday-whats-going-on

Eli Lilly shares are trading lower Friday, among other GLP-1 drug manufacturers, following Trump's comments that fat-loss ...

 novo-vs-lilly-vs-pfizer-who-wins-if-trump-slashes-the-price-of-weight-loss-drugs

Trump's promise to cut cost of Novo Nordisk A/S drug Ozempic from $1,300 to $150 shakes GLP-1 gold rush, with potential imp...

 eli-lilly-novo-nordisk-hims--hers-health-shares-move-lower-after-trump-calls-out-fat-loss-drugs

Shares of Eli Lilly and Novo Nordisk move lower in Thursday's after-hours session after President Trump indicated weight-lo...

Core News & Articles

https://www.youtube.com/watch?v=xagrobF4q1k 

 hims--hers-stocks-150-surge-is-all-fundamentalsno-novo-no-problem

Hims & Hers (HIMS) has seen surprising success, up 150% YTD, driven by their new menopause specialty and refocusing on heal...

 update-novo-nordisk-says-us-fda-approves-addition-of-intestinal-obstruction-severe-constipation-from-recent-major-changes-on-wegovys-prescribing-info

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf

 novo-nordisk-says-us-fda-approves-wegovys-supplemental-new-drug-application-as-amended-for-labeling-with-minor-editorial-revisions

https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215256s024lbl.pdf

 omeros-stock-skyrockets-after-novo-nordisk-strikes-21b-rare-disease-drug-deal

Omeros stock jumps 164% as Novo Nordisk acquires global rights to zaltenibart, with potential milestones reaching $2.1 billion ...

 novo-nordisk-begins-round-of-layoffs-in-united-states-sources-say--reuters

https://www.reuters.com/world/novo-nordisk-begins-round-layoffs-united-states-sources-say-2025-10-15/

Core News & Articles

Zaltenibart has best-in-class potential across multiple rare blood and kidney disorders and will enhance Novo Nordisk's Rar...

 bmo-capital-maintains-market-perform-on-novo-nordisk-raises-price-target-to-55

BMO Capital analyst Evan David Seigerman maintains Novo Nordisk (NYSE:NVO) with a Market Perform and raises the price target...

 why-is-scholar-rock-stock-trading-lower-on-monday

Scholar Rock stock falls as FDA issues Form 483 to Catalent; company to meet FDA, while apitegromab shows lean mass preservatio...

Core News & Articles

https://scholarrock.com/our-company/newsroom/update-on-third-party-manufacturing-site/

 novo-nordisk-responds-to-earlier-report-of-halting-cell-therapy-for-diabetes-says-decided-to-discontinue-our-cell-therapy-rd-efforts-in-process-of-identifying-partners-with-right-capabilities--manufacturing-capacity-to-further-develop-innovations-we-will-not-share-additional-details-about-individual-sites-or-areas-affected-by-discontinuation-of-cell-therapy-rd-efforts

- Reuters

 bill-gates-and-paho-push-to-make-weight-loss-drugs-accessible-in-low-income-nations

Bill Gates and PAHO are working to make weight-loss drugs like Wegovy and Mounjaro more affordable for low-income countries.

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION